CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 270 enrolled
Drug / intervention
Metronidazoledrug
Likely dose
Metronidazole 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01018095
NCT01018095Phase 4Completed
CompareCT.gov

Randomized Phase IV Trial of Metronidazole Single Dose Versus 7 Day Dose for Treatment of Trichomonas Vaginalis Among HIV-infected Women

Tulane University Health Sciences Center·interventional·Posted Nov 23, 2009·Updated Dec 20, 2016

In Brief

A Phase 4 clinical trial evaluating Metronidazole for Trichomonas Infections and HIV Infections. Completed, enrolled 270 participants across 5 sites.

Detailed Summary

The purpose of this study is to determine if the 2 gram single dose of metronidazole is as effective as the 7 day 500 mg BID dose for treatment of Trichomonas vaginalis (TV) among HIV-infected women.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTrichomonas Infections, HIV Infections
CountriesUnited States
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 23, 2009
Enrollment StartMay 1, 2005
Primary CompletionJul 1, 2009
Study CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 16.6 years ago

Interventions

Metronidazoledrug

2 gm single dose versus 7 day 500 mg BID dose